Articles |

Benefits of High-dose IV Immunoglobulin in Patients With Severe Steroid-Dependent Asthma FREE TO VIEW

Lawrence P. Landwehr; John D. Jeppson; Michael G. Katlan; Beth Esterl; David McCormick; Daniel L. Hamilos; Erwin W. Gelfand
Author and Funding Information

Affiliations: From the Department of Pediatrics, National Jewish Medical and Research Center, Denver, CO.,  From the Department of Medicine, National Jewish Medical and Research Center, Denver, CO.,  From the Department of Biostatistics, National Jewish Medical and Research Center, Denver, CO.

Erwin W. Gelfand, MD, National Jewish Medical and Research Center, 1400 Jackson St, Denver, CO 80206; e-mail: gelfande@njc.org

1998 by the American College of Chest Physicians

Chest. 1998;114(5):1349-1356. doi:10.1378/chest.114.5.1349
Text Size: A A A
Published online


Study objective: To determine the efficacy of IV immunoglobulin (IVIg) in severe asthma to reduce steroid requirements.

Design: Pre- and posttreatment measurements were analyzed using Dunnett's multiple comparison procedure.

Setting: Hospital clinical research center.

Patients: Eleven adolescents and adults with severe, steroid-dependent asthma enrolled over a 14-month period.

Interventions: IVIg was administered at a dose of 2 g/kg every 4 weeks for a total of seven infusions.

Measurements and results: Steroid requirements, pulmonary function including lung volumes, symptom scores, bone densitometry, and airway reactivity monitored by methacholine challenge were followed over the course of 7 months. A significant decrease in steroid usage was achieved. Despite substantial steroid reduction, the patients demonstrated improvement in their pulmonary function and symptom scores. The responses to methacholine challenge were unaffected by IVIg treatment.

Conclusions: IVIg provides a potentially important adjunctive therapy in severe asthma, reducing oral steroid requirements and steroid side effects without deterioration of lung function.




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
[Oral steroids downgraded, biologics upgraded]. MMW Fortschr Med 2016;158(10):86.
Management of asthma.
Singapore Ministry of Health | 7/18/2008
Treatment of acute exacerbation of asthma.
Finnish Medical Society Duodecim | 1/25/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543